Clinical Trials
13 trialsNCT00085553 2018-05-18
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00244972 2017-04-27
Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00049387 2015-04-15
Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00383474 2015-04-15
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
National Cancer Institute (NCI)
Phase 1 Completed
NCT02227901 2014-12-23
Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005845 2013-12-16
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed
NCT00124644 2013-05-03
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00005842 2013-02-11
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005967 2013-02-11
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00101296 2013-02-04
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00112853 2013-01-09
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00022451 2012-03-15
Tipifarnib in Treating Young Patients With Refractory Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00006199 2005-06-24
Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)
National Center for Research Resources (NCRR)
Phase 1 Unknown